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Abstract
Molecules associated with TGF-β superfamily such as BMPs and TGF-β are key regulators of
inflammation, apoptosis and cellular transitions. Here, we demonstrate that the BMP receptor
activin–like kinase 3 (Alk3) is elevated early in response to kidney injury and its deletion in the
tubular epithelium leads to enhanced TGF-β1 / Smad3 signaling, epithelial damage and fibrosis,
suggesting a protective role for Alk3 mediated signaling. Structure–function analysis of Alk3 /
BMP / BMPRII ligand–receptor complex coupled with synthetic organic chemistry led us to
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construct a library of small peptide agonists of BMP signaling that function via Alk3 receptor.
One such peptide agonist, THR–123, suppressed inflammation, apoptosis epithelial–to–
mesenchymal transition program, and reversed fibrosis in mouse models of acute and chronic
injury. Combining THR–123 and angiotensin–converting enzyme inhibitor, captopril, exhibited
additive therapeutic benefit in controlling fibrosis. Our studies demonstrate that BMP signaling
agonists constitute a new line of therapeutic agents with a potential utility in the clinic to induce
regeneration, repair and reverse fibrosis.
Introduction
Bone morphogenetic protein–7 (BMP7), a member of the transforming–growth factor
(TGF)-β superfamily, acts as an antagonist of TGF-β–mediated activity1-3. BMP7 binds to
three type I receptors, activin–like kinase (Alk) –2, –3, –6 and a type II receptor, BMPR–II,
and displays distinct activities in different cell types4, exhibiting anti–inflammatory and
anti–apoptotic functions as well as promoting bone formation5,6. It is essential that BMPs
interact with both type I and type II receptors for signaling and ligand–induced activation
induces intrinsic serine / threonine kinase activity that triggers phosphorylation of receptor–
regulated Smads (R–Smads). Smad2 and Smad3 are phosphorylated by type I receptors of
TGF-β and activin, while Smad1, Smad5 and Smad8, act downstream of BMP type I
receptors4. High affinity receptors for BMP7 are shown to be present in kidney epithelial
cells, and are speculated to mediate BMP7 actions in the kidney7,8.
End stage renal disease (ESRD) of various etiologies exhibit a positive correlation with the
degree of tubulo–interstitial fibrosis9-13. Here we demonstrate that Alk3 functions to inhibit
fibrosis by controlling inflammation, apoptosis and induction of an epithelium–to–
mesenchymal (EMT) program. Peptide agonists of BMP signaling that bind to Alk3 were
generated and one such peptide, THR–123, controls fibrosis and induces kidney
regeneration.
Results
Alk3 is a negative regulator of fibrosis
Reno–protective properties and anti–fibrotic effects of BMP7 have been demonstrated in
various kidney disease models2,14-16, and BMP7 expression is suppressed in acute and
chronic kidney injury17-20. We evaluated the expression levels of several BMP7 targets in
mice with chronic renal injury over time. Alk3 expression uniquely peaked after only one
week following kidney injury, and remained high between three to six weeks following
injury when compared to control kidneys (Fig. 1a, Supplementary Fig. 1a, b). At week 9,
Alk3 expression decreased when compared to control kidney (Fig. 1a), likely as a result of
depletion of Alk3 expressing cells. In contrast, BMP7 expression levels decreased the most
among all the molecules tested following kidney injury, reaching its minimum level at three
weeks following injury and remained low (Fig. 1a, Supplementary Fig. 1a, b).
In mice with nephrotoxic serum induced chronic kidney fibrosis (NTN) (Fig. 1b),
phosphorylated Smad1 (p–Smad1) accumulated in the nucleus of the tubules at week 1
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following injury. Interestingly, p–Smad1 labeling decreased at week 6 post kidney injury
(Fig. 1c), presenting a similar trend as that observed with Alk3 expression (Fig. 1a). These
results further suggest that BMP7 / Alk3 axis correlates negatively with renal epithelial
injury and interstitial fibrosis. To functionally address this observation, we deleted Alk3
receptor in the tubular epithelial cells.
We confirmed the specificity of γGT–Cre expression utilizing the R26R–Rosa–LSL–LacZ
mice21. Reporter analysis revealed that γGT–Cre; R26R–Rosa–LSL–LacZ mice exhibit
strong expression of LacZ in the proximal kidney tubules when compared to littermate
control mice [Cre (–); R26R–Rosa–LSL–LacZ mice] (Fig. 1d). LacZ was not expressed in
other organs, including the liver and hematopoietic compartment of these reporter mice
(γGT–Cre; R26R–Rosa–LSL–LacZ mice) (Supplementary Fig. 1 and data not shown).
Crossing of γGT–Cre mice with floxed alleles of Alk3 resulted in the excision of exon3 in
the Alk3 gene, leading to the absence of Alk3 protein expression in kidney tubule compared
to control Akk3 f/f mice without Cre–recombinase activity22,23 (Fig. 1e). NTN induced
severe crescentic glomerulonephritis with interstitial fibrosis initially in all groups of mice
analyzed (Fig. 1f). Six weeks after the induction of NTN, fibrosis was more severe in γGT–
Cre; Akk3 f/f mice (Alk3 deleted mice) compared to control mice (Fig. 1f). F4/80+
macrophage express Alk3, and such expression remained intact despite deletion of Alk3
using γGT–Cre mice, confirming that the accelerated fibrosis observed in these mice is
reflective of the deletion of Alk3 in proximal tubules (Supplementary Fig. 1d). Such
accelerated fibrosis in the Alk3 deleted mice was associated with enhanced activation of
TGF-β pathway, as demonstrated by the increased p–Smad2 in the nucleus of the tubular
epithelial cells (Supplementary Fig. 1e). Renal function as judged by blood urea nitrogen
(BUN) measurement was significantly higher in the Alk3 deleted mice with fibrosis when
compared to the control mice (Fig. 1g). This phenotype was not observed in γGT–Cre mice
and unchallenged γGT–Cre; Akk3 f/f mice (Supplementary Fig. 1f–g).
Inflammation associated with macrophage influx and renal epithelial apoptosis are
considered to be important instigators of renal fibrosis24 . Mice with Alk3 deletion in the
kidney tubular epithelium demonstrated increased influx of macrophages in association with
fibrosis (Supplementary Fig. 1h). Increased number of tubular epithelial cells exhibited co–
localization of both epithelial marker E–cadherin and mesenchymal marker, FSP1
(S100A4), indicative of an EMT program (Fig. 1h).
Design of the BMP signaling pathway agonists
Cyclic peptide agonists of the BMP signaling pathway were designed by identifying regions
of the 3-D structure of TGF-β225,26 and BMP727 most likely involved in receptor
interactions and by comparing side chain solvent accessibility with the regions of the TGF-β
super family aligned sequences having the highest variability27. To further refine the regions
of interest, we used a structure–variance analysis (SVA) program 28 that weighs physical–
chemical residue properties at each position based on their correlation with an activity. The
goal was to identify receptor–binding regions and then optimize the sequence for specific
BMP activities. The highest scoring residue positions were then mapped onto the 3-D
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structure of BMP727. Of the three structural regions identified 27, peptides designed around
the finger 2 loop proved to be the most promising. These are 16 residue long peptides of ~2
kDa molecular weight that are cyclized via a disulfide bond between the first and 11th
residue positions in order to stabilize loop and preserve a 3-D conformation similar to the
conformation in the finger 2 loop of BMP7 (Fig. 2a).
Preliminary screening for optimization was based on anti–inflammatory efficacy in an in
vitro cell–based assay using a human renal tubular epithelial cell line (HK–2). The assay
tested the ability of compounds to reverse the increase in the production of cytokine IL–6
that resulted from stimulation of the cells with tumor necrosis factor (TNF)-α
(Supplementary Fig. 1i). Sequence–activity analysis was carried out using the SVA
program. After six optimization cycles, a couple of compounds emerged as the lead
candidates. One such candidate, THR–123 (Fig. 2a), was further evaluated in other relevant
receptor-binding and anti–fibrosis assays.
First, we analyzed specific binding of the extra cellular domains (ECD) of the several type I
receptors of BMPs to THR–123. Binding of cold BMP7 to immobilized receptor ECDs was
determined by competition with 125I–labeled BMP7 and analyzed by scatchard analysis to
determine effective dissociation constants of BMP7 for each of the receptor ECDs. To
obtain an estimate of the effective dissociation constant of THR–123 for a particular
receptor ECD, the dissociation constant for cold BMP7 was multiplied by the ratio of the
ED50 of THR–123 to the ED50 for cold BMP7. The data demonstrated that THR–123
competes with BMP7 for Alk3 and to some extent with Alk2 (data not shown), whereas
absolutely no competition was observed with Alk6 (Fig. 2b), suggesting that of the three
known BMP type I receptors, Alk3 is the predominant target for THR–123. The ~104 ratio
of competitive EC50 binding of THR–123 to that of BMP7 with Alk3 is likely due to three
effects: first, BMP7 binds as a dimer to two type I receptor ECD's (they are cloned as two
copies for each Fc fragment), whereas, monomeric THR–123 binds to one type I receptor,
therefore its affinity is the square root of the observed dimer affinity. Second, due to the
difference in size of the molecules (the molecular weight of BMP7 dimer is ~19 times
greater than THR–123), the available surface area of the BMP7 monomer is ~3 times that of
the THR–123 monomer; and finally, when a weakly binding compound competes with a
stronger one, the ratio of the EC50's overestimates the ratio of the KD's by a factor of 2.
Although these results do not inform on the in situ binding affinity of the peptides to native
BMP receptors, they however support selective binding capacity of THR–123 to Alk3 and
Alk2 but not Alk6.
The stability of THR–123 in whole blood and plasma was tested in vitro. In PBS–mannitol
buffer, THR–123 was stable for over 400 minutes (Fig. 2c). In rat plasma, THR–123 is
slowly degraded with a half–life of 358 minutes, while in whole blood, THR–123 degraded
rapidly (half–life of 70 minutes) (Fig. 2c). The persistence of THR–123 in systemic
circulation was evaluated using i.v. administered 125I–labeled compound and following the
radioactivity decay. In both plasma and whole blood, THR–123 levels immediately
decreased within 5 minutes (by almost 90%), suggesting a very short half–life of THR–123
in the alpha–phase (Fig. 2d). Beta–phase assessment of 125I–THR–123 indicates a half–life
of 55–58 min (Fig. 2e). Six hours after intravenous administration of 125I–THR–123, the
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majority of the radioactivity was still localized in the kidney and bladder (Fig. 2f),
suggesting that THR–123 accumulates in the kidney and is excreted, via the bladder, into the
urine. Orally administrated 125I–labeled THR–123 localized primarily to the kidney cortex
within one hour after ingestion and peaked at about 3 hours (Fig. 2g). Twenty–four hours
after ingestion, most of the 125I–THR–123 associated radioactivity was cleared from the
kidney (Fig. 2g).
THR–123 inhibits inflammation, apoptosis and EMT Program
Inflammation is a key feature in renal fibrosis. BMP7 displays an anti–inflammatory
activity6,29, thus prompting us to investigate the effect of THR–123 on the expression of
several pro–inflammatory cytokines in human renal tubular epithelial cell line (HK–2 cells).
BMP7 and THR–123 inhibited TNF-α induced IL–6 production in dose dependent manner
(Supplementary Fig. 2a). THR–123 also inhibits TNF-α–induced IL–8 and ICAM–1
production in HK–2 cells (Supplementary Fig. 1a), suggesting that similar to the function
of BMP7, THR–123 exhibits anti–inflammatory properties.
BMP7 is also reported to protect tubular epithelial cells (TECs) from apoptosis18. TGF-β–
induced apoptosis in TECs was analyzed by Annexin V labeling (Supplementary Fig. 2b).
BMP7 and THR–123 exhibited similar anti–apoptotic activity, while such anti–apoptotic
activity was not detected when a control scrambled cyclic peptide was used
(Supplementary Fig. 2b, c). Hypoxia induced apoptosis of TECs was also inhibited by
BMP7 and THR–123 (Supplementary Fig. 2c). Additionally, cisplatin induced apoptosis
was inhibited by THR–123 (Supplementary Fig. 2d).
BMP7 has been shown to inhibit TGF-β induced epithelial–to–mesenchymal transition
(EMT) program2. Similar to BMP7, THR–123 inhibited TGF-β induced EMT program
(Supplementary Fig. 3). TGF-β inhibited E–cadherin expression, while both BMP7 and
THR–123 restored TGF-β–suppressed E–cadherin to normal levels (Supplementary Fig.
3b, c). Control cyclic scrambled peptide exhibited insignificant effect on the EMT program
(Supplementary Fig. 3a, b). Such effect of THR–123 is associated with Smad1/5
phosphorylation (p-Smad1/5) (Supplementary Fig. 3d). TGF-β induced expression of
genes associated with EMT program such as snail (Sna) and CTGF was inhibited by THR–
123 (Supplementary Fig. 3e). After 48 hours of incubation with TGF-β and epidermal
growth factor (EGF), TECs exhibited mesenchymal features indicative of EMT
(Supplementary Fig. 3f, g). The TGF-β–induced EMT in these cells was reversed by the
treatment with BMP7 or THR–123 (Supplementary Fig. 3f–h). Control peptide revealed
insignificant effect on EMT induction (Supplementary Fig. 3f–h). THR–123–induced
reversal of EMT was associated with restoration of E–cadherin expression (Supplementary
Fig. 3g).
THR–123 induces regeneration and reverses fibrosis
We analyzed the effect of THR–123 on acute renal injury using the ischemic re–perfusion
injury (IRI) model in mice. Seven days after IRI, control mice exhibited renal morphology
consistent with acute renal tubular necrosis characterized by tubular dilatation and flattened
epithelial cells with eosinophilic homogenous cytoplasm (Supplementary Fig. 4a). THR–
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123–treated mice displayed significantly less tubular damage in IRI kidney when compared
to control mice, yet blood urea nitrogen levels were similar in both groups (Supplementary
Fig. 4a).
Unilateral ureteral obstruction (UUO) is a well–established model of severe renal interstitial
injury and fibrosis (Supplementary Fig. 4b). Five days after UUO, kidneys display
significantly increased interstitial volume when compared to normal kidney
(Supplementary Fig. 4b). Oral administration of THR–123 (5 mg.Kg−1 or 15 mg.Kg−1)
inhibited interstitial volume expansion in UUO kidneys when compared to untreated mice
(Supplementary Fig. 4b). Seven days after UUO, kidneys exhibited severe fibrosis with
increased interstitial volume (Supplementary Fig. 4b). Intraperitoneal administration of
BMP7 ameliorated interstitial volume expansion when compared to control mice
(Supplementary Fig. 4c). Both intraperitoneal and oral administration of THR–123
inhibited fibrosis (Supplementary Fig. 4c). Decreased tubular damage with THR–123
treatment was associated with decreased expression of matrix components such as
fibronectin (Fn1) and type I collagen (Col4a1) (Supplementary Fig. 4d).
We next analyzed the effect of THR–123 on the nephrotoxic nephritis induced by sheep
anti–glomerular antibodies (NTN) model. Kidneys with NTN exhibit severe crescentic
glomerulonephritis with interstitial damage and fibrosis1,30. Such lesions develop in a
progressive manner in the CD–1 mice (Fig. 3a, Supplementary Fig. 5a). Six weeks
following NTN induction, mice exhibited severe crescentic glomerulonephritis with severe
interstitial damage and fibrosis (Fig. 3b). THR–123 treatment (initiated at six weeks
following NTN induction) improved glomerular lesion (sclerosis) and tubular atrophy and
fibrosis (Fig. 3b), associated with decreased expression of matrix components such as
fibronectin (Fn1) and type I collagen (Col4a1) (Supplementary Fig. 5b). Blood urea
nitrogen was decreased after THR–123 treatment (Fig. 3c). We identified tubular cells with
EMT program, as being positive for both FSP1 and E–cadherin. Similar to previous reports2,
EMT program was evident in NTN kidneys when compared to normal kidney (Fig. 3d).
THR–123 treatment significantly decreased the number of cells exhibiting an EMT program
(Fig. 3d). NTN kidneys exhibited increased Mac–1 and F4/80 positive macrophages when
compared to control normal kidney; and THR–123 treatment inhibited accumulation of
macrophage (Supplementary Fig. 5c, d). THR–123 treated kidneys presented with
increased accumulation of p-Smad1/5, revealing a possible stimulation of Alk3–mediating
pathway (Supplementary Fig. 5e).
Alport syndrome is a inherited kidney disease caused by genetic mutations in genes
encoding for type IV collagen proteins31. The mice deficient in alpha 3 chain of type IV
collagen chain (COL4A3KO mice) mimic renal disease associated with Alport syndrome.
At 16 weeks of age, COL4A3KO mice exhibited increased glomerular abnormality, tubular
atrophy and fibrosis when compared to wild–type kidney (Supplementary Fig. 6a). While
THR–123 treatment did not alter glomerular abnormalities (Supplementary Fig. 6a–b), it
significantly inhibited tubular atrophy and interstitial fibrosis (Supplementary Fig. 6a–b).
Blood urea nitrogen levels were increased in COL4A3KO mice when compared to wild–
type mice and THR–123 significantly improved blood urea nitrogen level in COL4A3KO
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mice (Supplementary Fig. 6b). In COL4A3KO kidney, the number of cells exhibiting EMT
program was significantly higher when compared to wild–type kidney (Supplementary Fig.
6d). THR–123 treatment inhibited such acquisition of an EMT program (Supplementary
Fig. 6e). Macrophage infiltration in COL4A3KO kidney was increased when compared to
control kidney and THR–123 treatment inhibited macrophage infiltration (Supplementary
Fig. 6e). THR–123 treated COL4A3KO kidneys were associated with an increase in p–
Smad1/5 (Supplementary Fig. 6f).
Next, we evaluated the efficacy of THR–123 in controlling diabetic nephropathy (DN) in
mice. CD–1 mice injected with streptozotocin (STZ) exhibit increased glomerular mesangial
matrix with increased glomerular surface area associated with interstitial damages by six
months when compared to control mice, suggesting advanced DN (Fig. 4a, Supplementary
Fig. 7a). While neither BMP7 nor THR–123 inhibited glomerular surface area increase in
diabetic mice, both BMP7 and THR–123 inhibited mesangium expansion in STZ–induced
six month DN (Fig. 4b). Furthermore, THR–123 treatment (5–6 months) substantially
reversed mesangial matrix expansion when compared to mice with five months of DN
(before THR–123 administration began) (Fig. 4b). DN mice displayed increased tubular
atrophy and interstitial volume when compared to control mice (Fig. 4b). Treatment with
BMP7 (1–6 months treatment) or THR–123 (5–6 months treatment) inhibited tubular
atrophy and interstitial volume increase (Fig. 4b). THR–123 substantially reversed tubular
atrophy and interstitial volume expansion (Fig. 4b). Blood urea nitrogen levels increased in
DN when measured at five and six month following STZ administration (Fig. 4c). Both
BMP7 and THR–123 significantly reversed renal dysfunction in DN (Fig. 4c), inhibited
induction of an EMT program (Fig. 4d), and reduced macrophage infiltration
(Supplementary Fig. 7b, c). THR–123 treated kidneys of mice with DN were also
associated with increased accumulation of p-Smad1/5 (Supplementary Fig. 7d).
Angiotensin–converting enzyme inhibitor (ACE–I) is a well–established drug used to
control progression of several chronic progressive kidney diseases including diabetic
nephropathy32,33. Therefore, we tested THR–123 and ACE–I [captopril (CPR)] in
combination in mice with advanced diabetic kidney disease associated fibrosis. Seven
months after induction of diabetes, DN kidneys displayed a significant increase in
glomerular surface area and mesangial matrix deposition (Fig. 5a). CPR and CPR / THR–
123 combination treatment was initiated in mice with severe DN at seven months following
DN induction. Glomerular surface area remained identical in all groups analyzed (Fig. 5b).
CPR treatment did not inhibit progression of mesangial matrix expansion in these
experiments, but a combination of CPR with THR–123 significantly reduced mesangial
expansion and substantially reversed it when compared to untreated control mice (Fig. 5b).
Between seven to eight months (late–stage) after induction of diabetes, DN kidney exhibited
tubular atrophy and interstitial volume expansion (Fig. 5b). CPR alone partially inhibited
tubulo–interstitial alterations in DN kidney while a combination of CPR with THR–123
completely inhibited tubular atrophy and interstitial volume expansion (Fig. 5b). Blood urea
nitrogen level analysis revealed that DN mice exhibit significant renal function deterioration
between seven and eight months after induction of diabetes (Fig. 5c). CPR did not (P =
0.08), but combination therapy significantly inhibited the progressive loss of renal function
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(Fig. 5c). EMT program was inhibited by CPR alone and also by the CPR / THR–123
combination treatment (Fig. 5d). Both CPR and CPR / THR–123 combination therapy
inhibited macrophage infiltration (Supplementary Fig. 7e). CPR significantly inhibited
apoptosis in diabetic kidney and CPR / THR–123 combination therapy exhibited additive
anti–apoptotic effects (Supplementary Fig. 7f). CPR / THR–123 treated kidneys were
associated with increased accumulation of p–Smad1/5 (Supplementary Fig. 7g). Blood
sugar level and body weight were not altered in all the groups analyzed when compared to
untreated diabetic mice at similar age (Supplementary Fig. 7h, i).
Loss of Alk3 prevents THR–123 activity
Binding of THR–123 to the Alk3 receptor induced actions that mimic BMP7 (vide supra).
Our experiments suggested that THR–123 functions to suppress renal injury and fibrosis by
inhibiting inflammation, apoptosis and EMT program. To functionally validate the target of
THR–123 in exerting such reno–protective activity in mice, we tested the efficacy of THR–
123 in the Alk3 deleted mice subjected to renal injury. The Alk3 deleted mice and their
littermate (control) mice were subjected to IRI. The mice with Alk3 deficiency exhibit
accelerated acute renal injury when compared to the control mice (Supplementary Fig. 8a).
THR–123 inhibited renal injury in the control mice but does not exhibit therapeutic effect in
the Alk3 deleted mice (Supplementary Fig. 8a). Alk3 dependent action of THR–123 in the
control mice was associated with the reduction in macrophage accumulation
(Supplementary Fig. 8b) and decreased tubular apoptosis (Supplementary Fig. 8c).
Accelerated renal failure and fibrosis was observed in Alk3 deleted mice with NTN when
compared to the control mice (Fig. 6a). We demonstrate that while THR–123 was successful
in controlling renal injury and fibrosis in the control mice, it has no efficacy in the Alk3
deleted mice (Fig. 6a). Such therapeutic effects of THR–123 on control mice with NTN was
associated with the inhibition of macrophage accumulation in the kidney and EMT program
in the tubules, whereas THR–123 inhibited neither macrophage accumulation (Fig. 6b) nor
induction of an EMT program (Fig. 6c) in Alk3 deleted mice with NTN. THR–123 inhibit
apoptosis in wild type kidney with NTN but had no effect on apoptosis in Alk3 deleted mice
(Supplementary figure 8d). Finally, THR–123 restored renal function in control mice with
NTN, but such reno–protective effect of THR–123 was not realized in Alk3–deleted mice
(Fig. 6d).
Discussion
TGF-β super–family proteins wield considerable influence on the pathogenesis of renal
fibrosis34. Many of the molecules in this family, most importantly TGF-β1 and TGF-β2,
have been identified as positive regulators of fibrosis due to their ability to recruit
myofibroblasts, facilitate EMT program, influence inflammation and induce epithelial cell
apoptosis2,5,18,29. While much focus has been placed on the positive role of TGF-β1 in
fibrosis, BMP7 (another molecule in the TGF super–family) was found to inhibit and
reverse fibrosis2. BMP7 action is realized via its anti–inflammatory, anti–apoptosis and
EMT suppressive actions2,5,18,29. BMP7 counter–balances the actions of TGF-β1 via Smad–
dependent pathways2. In this regard, BMP7 can also bind to Alk6 receptor on osteoblasts
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and induce bone formation35-38. In the kidney, tubular epithelial cells predominantly express
Alk3 receptor39. Therefore, an ideal therapeutic candidate would be one that binds to Alk3
but not to Alk6 receptor, induces BMP signaling but does not induce osteogenic activity.
While the levels of BMP7 decreases in the context of renal injury, the role of Alk3 in the
progression of renal disease is unknown17–20. Our results also suggested that expression of
BMP7 and Alk3 inversely correlate with progression of fibrosis supporting the notion that
BMP7 plays a likely reno–protective role, in opposition to TGF-β1 action2. Similarly, in this
study we identify that Alk3 is also a positive regulator of renal health during injury. It
responds to renal injury in a protective fashion and its loss augments the progression of renal
fibrosis. These results, coupled with the anti–fibrotic activity of BMP7, provided the
necessary rationale design a new class of molecules that serve as BMP signaling agonist via
their binding to Alk3. One such candidate molecule, THR–123, was further tested for
mechanism of action and therapeutic efficacy.
THR–123 suppressed progression of kidney disease and substantially reversed established
kidney fibrosis without inducing any osteogenic activity. Interestingly, while Alk3 receptor
expression likely decreases at end–stage kidney disease, THR–123 still exhibits substantial
activity. This suggests that such diminished level of Alk3 in not a rate–limiting factor for the
efficacy of THR–123. We show that a combination of THR–123 and captopril, an
angiotensin converting enzyme inhibitor, had an additive therapeutic effect in controlling
renal fibrosis associated with diabetic kidney disease. Collectively, our results indicate that
THR–123 inhibits inflammation, apoptosis, EMT program and reverses renal fibrosis. It is
possible that Alk2 receptor may also contribute to the action of THR–123, but experiments
using genetic mouse model suggest that such Alk2 mediated activity, if present, is minimal.
In summary, our study suggests that Alk3 receptor is a negative regulator of fibrosis when
kidney is injured. THR–123, a small peptide BMP signaling agonist that binds to Alk3 and
activates the Smad pathway, demonstrates therapeutic efficacy when administered orally to
mice with fibrosis. Such reno–protective properties mirrored the action of BMP7, the natural
ligand of Alk3, in the kidney. These pre–clinical studies offer insights into the use of BMP
signaling pathway agonists in the treatment of acute and chronic kidney injury.
Materials and Methods Summary
Mice
The Alk3 f/f mice were bred with γGT–Cre mice to generate mice with deletion of Alk3
receptors in proximal tubular cells. The γGT promoter used to generate the Cre expressing
mice was designed to express predominantly in the kidney proximal and distal tubules, with
undetectable expression in the liver. The mice were on Balb/C background. Type IV
collagen α3 chain knockout mice (COL4A3KO, C57Bl/6 background) mice were previously
described31. Nephrotoxic serum induced nephritis (NTN), ischemic reperfusion injury (IRI),
unilateral ureteral obstruction (UUO), and diabetic nephropathy (DN) models are described
in online method section. Dose and routes for treatment with THR–123, BMP7 and captopril
(and combination therapy) are detailed in the online method section. All animal experiments
were reviewed and approved by the Beth Israel Deaconess Medical Center Institutional
Animal Care and Use Committee.
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Synthesis and pharmacokinetics of THR–123
Radio–ligand receptor competitive binding assays of THR–123 for specific for individual
type I receptors Alk3 and Alk6 was performed using highly purified extra–cellular domain
(ECD) of Alk3 or Alk6 (expressed as a fusion protein with Fc domain) immobilized on each
well. Peptide analog or unlabeled BMP7 was added, followed by 125I–labeled BMP7.
Radiolabeled BMP7 complex was counted in an auto–gamma counter. Unlabeled BMP7
served as a positive control in both assays. Concentration of THR–123 in systemic
circulation of Wistar rats was performed by measuring total radioactivity using automatic
gamma well counter in plasma and whole blood following i.v. injection of THR–123 (125I–
Tyr) via the tail vein. Freshly harvested rat blood (male Sprague–Dawley, 0.35kg body
weight), plasma and PBS mannitol buffer solution were spiked with THR–123 at a final
concentration of 0.1 mg.ml−1. Blood, plasma and buffer tubes were incubated at 37 °C for
up to 6 hours and duplicate samples of 500 μl (blood) and 250 μl (plasma and blood) were
analyzed at 0, 7.5, 15, 30, 60, 120, 240 and 360 minutes following injection of THR–123.
Samples were analyzed for THR–123 using an LC–MS–MS method having a limit of
detection of 1 μg.ml−1. For tissue distribution of THR–123, tissues were harvested six hours
after i.v. administration of 125I labeled THR–123 (125I–THR–123 ) in rats at a dose of 6.25
mg.kg−1 body weight, and were analyzed by automatic gamma well counter. Elimination of
THR–123 from the body following oral administration was evaluated by measuring
radioactivity in the kidneys of rats orally administrated 125I–THR–123 at a dose of 5
mg.kg−1 body weight.
Reagents
Monoclonal antibody for E–cadherin was purchased from BD Biosciences. Mac–1 antibody
was purchased from AbD Serotec. F4/80 and BMP7 antibody was purchased from Abcam.
p–Smad1/5 antibody was purchased from Cell Signaling Technology. Alk3 and E–cadherin
antibodies were purchased from Santa Cruz Biotechnology. For western blot analyses, Alk3
antibody was purchased from EMD Millipore. Measurements of BUN were performed using
the QuantiChrom™Urea Assay Kit (BioAssay System) or DIUR–500 QuantiChrom™ Urea
Assay Kit (Gentaur). Measurements of urine albumin and urine creating were performed
using the QuantiChrom™ Assay for albumin (DIAG-500) and creatinine (DICT-250) Kit
(BioAssay System). Details for morphormetric analyses of histological findings are listed in
the online method section.
Quantitative PCR analysis
Total RNA was isolated from the kidney by Trizol/Invitrogen PureLink RNA Mini Kit for
RNA extraction. Ten nanograms of total RNA were used for generating complementary
cDNA using the TaqMan One–Step RT–PCR Master Mix (Applied Biosystems).
Quantitative PCR was performed to analyze the gene expression profile of listed genes using
ABIprism 7,000 (Applied Biosystems). Gene list and primer sequences are listed in online
method section.
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Detection of LacZ
Kidney samples (1 mm2) from six weeks–old R26R–Rosa–LSL–LacZ mice 23 with or
without Cre–recominase expresssion were fixed at 4 °C for 4 hours in 4%
paraformaldehyde. Samples were washed 3 times with PBS pH 7.3 and then stained
overnight at 37 °C with LacZ staining buffer (1mg.ml−1 X–gal, 35 mM potassium
ferrocyanide, 35 mM potassium ferricyanide, 2 mM MgCl2, 0.02% NP–40, 0.01% sodium
deoxycholate in PBS). After washing with PBS pH 7.3, samples were embedded into
paraffin. Sections (10 μm) were then deparaffinized and counterstained with eosin.
Statistical analysis
The data were expressed as means ± s.e.m. Analysis of variance (ANOVA) followed by
Bonferroni/Dunn's test for multiple comparisons of mouse samples were used to determine
significance. Student's T–test analysis was used for single parameter comparisons. Statistical
significance was defined as P < 0.05. Graph–pad Prism software was used for statistical
analysis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Alk3 and BMP7 expression inversely correlate in kidneys developing progressive injury and fibrosis
(a) Gene expression of indicated genes in kidneys of mice before (day 0) and after nephrotoxic serum nephritis (NTN) induction
(1 week, 3 weeks, 6 weeks and 9 weeks after induction). (b) Representative MTS staining of control kidneys and kidneys from
mice at one and six weeks following NTN. Scale bar: 50 μm. (c) Representative picture of kidneys from control mice and from
mice at one and six weeks following NTN labeled with antibodies against phosphorylated Smad1 (p–Smad1). Scale bar: 50 μm.
(d) Beta–galactosidase substrate staining of kidneys of control mice (left) and γGT–Cre; R26R–Rosa–LSL–LacZ reporter mice
(right) and eosin counter stain. Scale bar: 50 μm, arrows: positive LacZ staining. (e) Representative picture of kidneys from
control Alk3 f/f (left) and γGT–Cre; Alk3 f/f mice (right) labeled with antibodies against Alk3. Scale bar: 100 μm. (f)
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Representative MTS staining (left) of NTN kidney from γGT–Cre; Alk3 f/f mice (n = 6) and littermate control mice (Alk3 f/f, n
= 4) and morphometric quantification (right) of fibrosis in NTN kidney from control (Alk3 f/f) and γGT–Cre; Alk3 f/f mice.
Scale bar: 50 μm. (g) Blood urea nitrogen measurement 60 days following NTN in γGT–Cre; Alk3 f/f mice (n = 5) and
littermate control mice (n = 3). (h) Representative images for E–cadherin / FSP1 immunolabeling of kidneys from control (Alk3
f/f) and γGT–Cre; Alk3 f/f mice (left) and percent of E–cadherin / FSP1 double positive tubule (right). Scale bar: 25 μm. Data
are expressed as mean ± s.e.m. * : P < 0.01.
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Figure 2. Synthesis and pharmacokinetics of THR–123
(a) Structure of BMP7 and THR–123. (b) Radio–ligand receptor competitive binding assays of THR–123 for Alk3 (left) and
Alk6 (right) extra–cellular domain (ECD) (expressed as a fusion protein with Fc domain). (c) Stability of THR–123 in plasma
and whole blood of rat following i.v. injection of 125I–THR–123, data are expressed as the ratio of THR–123 concentration at
the time of harvest (conc. at t) over THR–123 concentration at baseline (conc. at t = 0). (d–e) alpha phase (d) and beta phase (e)
of THR–123 clearance in systemic circulation of rats following i.v. injection of 125I–THR–123. (f). Tissue distribution of 125I–
THR–123 six hours after i.v. administration. (g) Visualization of radioactivity of orally administrated 125I–THR–123 in rat
kidneys at 1, 3, 6 and 24 hours after administration. Scale bar: 15 mm. Data are expressed as mean ± s.e.m.
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Figure 3. THR–123 reverses renal fibrosis in mice with nephrotoxic serum nephritis
(a) Representative MTS staining of kidney from untreated control mice (n = 5) (left panel); six weeks following NTN (n = 6,
NTN, 6 weeks) (middle left panel); nine weeks post NTN (NTN, 9 weeks) (middle right panel); and nine weeks NTN with
THR–123 administered starting at week 6 (NTN, 9 weeks + THR–123 (6–9 weeks)) (left panel), Scale bar: 40 μm. (b)
Morphometric analysis from control mice (n = 5), mice after 1 (n = 6), 3 (n = 8), and six weeks following induction of NTN (n =
6), and mice at nine weeks following NTN with THR–123 administered starting six weeks following NTN (THR–123 (6–9
weeks) (n = 6)), assessing percent of glomerulosclerosis score (left), tubular atrophy index (middle), and fibrosis index (left). (c)
Blood urea nitrogen measurement for mice six weeks following NTN (n = 3), nine weeks (n = 5), and nine weeks following
NTN with THR–123 administered starting at week 6 following NTN (n = 5). (d) Representative images of E–cadherin / FSP1
immunolabeling of kidney from control untreated mice (left panel), six weeks following NTN (middle left panel), nine weeks
(middle right panel), and nine weeks following NTN with THR–123 administered starting at week 6 following NTN (right
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panel) and percent of E–cadherin / FSP1 double positive tubule assessed by counting the number of double–labeled tubules
(right). Scale bar: 25 μm. Data are expressed as mean ± s.e.m. ** : P < 0.01, * : P < 0.05.
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Figure 4. THR–123 reverses fibrosis associated with diabetic nephropathy
(a) Representative histological PAS (upper panels) and MTS (lower panels) staining of kidney sections of control mice (n = 5,
left panel), five months following streptozotocin–induced diabetic nephropathy (DN) (n = 6, 2nd panel from the left), six months
following DN (n = 10, middle panel), six months following DN and treated with BMP7 from one to six months following DN (n
= 4, 4th panel) or THR–123 from five to six month following DN (n = 9, right panel). Scale bar upper panels: 10 μm, scale bar
lower panels: 50 μm. (b) Morphometric analysis of glomerular surface area (top left), mesangial matrix (top right), tubular
atrophy (bottom left) and relative interstitial volume (bottom right). (c) Blood urea nitrogen measurement of control mice, five
months following DN, six months following DN, six months following DN and treated with BMP7 from one to six months and
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six months following DN and treated with THR–123 from one to six months, and urine albumin over urine creatinine ratio of
indicated experimental groups. (d) Representative images of E–cadherin / FSP1 immunolabeling of kidney of indicated
experimental groups and percent of E–cadherin / FSP1 double positive tubule assessed by counting the number of double–
labeled tubules. Scale bar 25 μm. Data are expressed as mean ± s.e.m. * : P < 0.01.
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Figure 5. A combination of captopril and THR–123 inhibits progression of fibrosis associated with advanced diabetic nephropathy
(a) Representative histological PAS (upper panels) and MTS (lower panels) staining of kidney sections of mice seven months
following streptozotocin–induced diabetic nephropathy (DN) (n = 2), eight months following DN induction (n = 3), eight
months following DN induction and treated with captopril (CPR, n = 3), and eight months following DN induction and treated
with combination of CPR and THR–123 (n = 4). Scale bar upper panels: 10 μm, scale bar lower panels: 50 μm. (b)
Morphometric analysis of glomerular surface area (top left), mesangial matrix (top right), tubular atrophy (bottom left) and
relative interstitial volume (bottom right) of indicated experimental groups. (c) Blood urea nitrogen measurement in indicated
experimental groups. (d) Representative images of E–cadherin / FSP1 immunolabeling of kidney from indicated experimental
Sugimoto et al. Page 21
Nat Med. Author manuscript; available in PMC 2014 April 24.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
groups and percent of E–cadherin / FSP1 double positive tubules. Scale bar: 25 μm. Data are expressed as mean ± s.e.m. ** : P
< 0.01, * : P < 0.05, # : P = 0.08, ns: not significant.
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Figure 6. Alk3 is a functional receptor for the activity of THR–123
(a) Representative MTS staining picture of Alk3 f/f and γGTCre; Alk3 f/f mice six weeks after NTN and treated with PBS or
THR–123 (n = 4 in each group). And morphometric analyses of interstitial fibrosis in kidneys of mice the indicated
experimental groups. Scale bar: 50 μm. (b) Representative images of F4/80 immunofluorescence in the indicated experimental
groups and quantitation of the number of F4/80+ macrophages (Mϕ) per field of view. Scale bar: 25 μm. (c) Representative
images of E–cadherin / FSP1 immunolabeling of kidney from indicated experimental groups and percent of E– cadherin / FSP1
double positive tubules. Scale bar: 25 μm. (d) Blood urea nitrogen measurement in six and nine weeks of NTN in indicated
experimental groups (all n = 4). Data are expressed as mean ± s.e.m. ** : P < 0.01, * : P < 0.05. ns: not significant.
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